Skip to main content

17-05-2018 | Psoriatic arthritis | Review | Article

Disease Modification in Psoriatic Arthritis

Current Treatment Options in Rheumatology

Authors: MD, MS Alicia Lieberman, MD, MPH Christopher Ritchlin

Publisher: Springer International Publishing


Purpose of review

To provide clinicians evidence-based strategies to diagnose and treat psoriatic arthritis (PsA) patients based on involvement of the key domains peripheral arthritis, psoriasis and nails, axial involvement, dactylitis, and enthesitis, with the goal of improving outcomes for PsA patients by lessening joint pain and swelling and the degree of inflammation in the other key domains. It is also imperative to limit or eliminate progressive X-ray damage.

Recent findings

Evidence from phase III randomized trials demonstrate that agents that inhibit tumor necrosis factor (TNF), interleukin (IL)-17, and IL12/23 relieve joint inflammation and decrease or completely inhibit radiographic progression. Agents that block TNF and IL-17 are also effective for axial disease. Additional agents effective for psoriatic arthritis but without documentation of effect on progressive damage include apremilast, abatacept, and tofacitinib. Most agents have demonstrated efficacy for treatment of enthesitis and dactylitis.


A number of therapies that effectively treat the key domains of psoriatic arthritis are now available. Comprehensive assessment of patients to determine the extent and degree of domain involvement is essential to properly individualize treatment, improve outcomes, and limit progressive joint damage.

Please log in to get access to this content

Related topics